Crohn’s Disease Market Size, Share, Trends, Industry Analysis Report

Crohn’s Disease Market by Drug Class (Biologics, Amino Salicylates, Antibiotics, Corticosteroids, Immunomodulators and Others), Route of Administration (Subcutaneous, Intravenous and Oral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) and Geographical Regions (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America) – Trends and Forecast 2026-2035

  • Lowest Price Guaranteed

  • Slides
    213

  • Last Updated
    August 2026

  • View Count
    5696

Table of Contents

1. BACKGROUND
1.1. Context
1.2. Project Objectives

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis

2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis

2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources

2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach

3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis

3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics

4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Overview of Crohn’s Disease
6.2. Factors Contributing to Crohn’s Disease
6.3. Crohn’s Disease Treatment and Management
6.4. Future Perspectives

7. MARKET LANDSCAPE OF CROHN’S DISEASE DRUGS / THERAPY PROGRAMS
7.1. Methodology and Key Parameters
7.2. Crohn’s Disease Drugs / Therapy Programs: Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Clinical Stage of Development
7.2.3. Analysis by Type of Molecule
7.2.4. Analysis by Type of Biologic
7.2.5. Analysis by Type of Therapy
7.2.6. Analysis by Drug Frequency
7.2.7. Analysis by Route of Administration
7.2.8. Analysis by Target Pathway
7.2.9. Analysis by Target Patient Population
7.2.10. Analysis by Year of Establishment
7.2.11. Analysis by Company Size
7.2.12. Analysis by Location of Headquarters
7.2.13. Most Active Players: Number of Drugs / Therapy Programs

8. CLINICAL COMMERCIAL ATTRACTIVENESS
8.1. Methodology and Key Parameters
8.2. Key Parameters and Scoring
8.3. Phase III Drugs Targeting Crohn’s Disease

9. COMPANY PROFILES
9.1. Chapter Overview
9.2. AbbVie*
9.2.1. Drug Portfolio
9.2.2. Key Initiatives

* Similar details are presented for other companies mentioned below (based on information in the public domain)

9.3. Athos Therapeutics
9.4. Eli Lilly and Company
9.5. Janssen Biotech
9.6. Pfizer
9.7. Roche
9.8. Sanofi
9.9. Takeda

10. CLINICAL TRIAL ANALYSIS
10.1. Methodology and Key Parameters
10.2. Crohn’s Disease Market: Clinical Trial Analysis
10.2.1. Analysis by Trial Registration Year
10.2.2. Analysis by Trial Status
10.2.3. Analysis by Trial Registration Year and Trial Status
10.2.4. Analysis by Trial Registration Year and Patients Enrolled
10.2.5. Analysis by Trial Phase

10.2.6. Analysis by Trial Registration Year and Trial Phase
10.2.7. Analysis of Patients Enrolled by Trial Phase

10.2.8. Analysis by Study Design
10.2.8.1. Analysis by Design Masking
10.2.8.2. Analysis by Intervention Model
10.2.8.3. Analysis by Trial Purpose
10.2.8.4. Analysis by Allocation

10.2.9. Analysis by Target Patient Population

10.2.10. Most Active Sponsor / Collaborator: Analysis by Number of Registered Trials
10.2.10.1. Analysis by Leading Industry Players
10.2.10.2. Analysis by Leading Non-Industry Players

10.2.11. Analysis by Geography
10.2.11.1. Analysis of Clinical Trials by Trial Status and Geography
10.2.11.2. Analysis of Patients Enrolled by Trial Status and Geography

11. DRUG FAILURE ANALYSIS
11.1. Methodology and Key Parameters
11.2. Crohn’s Disease Market: Drug Failure Analysis
11.2.1. Analysis by Trial Phase
11.2.2. Analysis by Trial Status and Discontinuation
11.2.3. Analysis by Reason for Drug Discontinuation
11.2.4. Analysis by Study Start Year and Year of Termination
11.2.5. Analysis by Type of Sponsor / Collaborator

12. MARKET IMPACT ANALYSIS
12.1. Market Drivers
12.2. Market Restraints
12.3. Market Opportunities
12.4. Market Challenges

13. GLOBAL CROHN’S DISEASE MARKET
13.1. Key Assumptions and Methodology
13.2. Global Crohn’s Disease Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
13.2.1. Multivariate Scenario Analysis
13.2.1.1. Conservative Scenario
13.2.1.2. Optimistic Scenario

13.3. Key Market Segments

14. CROHN’S DISEASE MARKET, BY DRUG CLASS
14.1. Key Assumptions and Methodology
14.2. Crohn’s Disease Market: Distribution by Drug Class
14.2.1. Crohn’s Disease Market for Biologics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
14.2.2. Crohn’s Disease Market for Amino salicylates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
14.2.3. Crohn’s Disease Market for Antibiotics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
14.2.4. Crohn’s Disease Market for Corticosteroids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
14.2.5. Crohn’s Disease Market for Immunomodulators, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
14.2.6. Crohn’s Disease Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

14.3. Data Triangulation and Validation

15. CROHN’S DISEASE MARKET, BY ROUTE OF ADMINISTRATION
15.1. Key Assumptions and Methodology
15.2. Crohn’s Disease Treatment Market: Distribution by Route of Administration
15.2.1. Crohn’s Disease Market for Subcutaneous Route, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
15.2.2. Crohn’s Disease Market for Intravenous Route, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
15.2.3. Crohn’s Disease Market for Oral Route, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

15.3. Data Triangulation and Validation

16. CROHN’S DISEASE MARKET, BY DISTRIBUTION CHANNEL
16.1. Key Assumptions and Methodology
16.2. Crohn’s Disease Market: Distribution by Distribution Channel
16.2.1. Crohn’s Disease Market for Hospital Pharmacies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
16.2.2. Crohn’s Disease Market for Retail Pharmacies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
16.2.3. Crohn’s Disease Market for Online Pharmacies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

16.3. Data Triangulation and Validation

17. CROHN’S DISEASE MARKET, BY GEOGRAPHICAL REGIONS
17.1. Key Assumptions and Methodology
17.2. Crohn’s Disease Market: Distribution by Geographical Regions

17.2.1. Crohn’s Disease Market in North America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.1.1. Crohn’s Disease Market in the US: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.1.2. Crohn’s Disease Market in Canada: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

17.2.2. Crohn’s Disease Market in Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.2.1. Crohn’s Disease Market in Germany: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.2.2. Crohn’s Disease Market in the UK: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.2.3. Crohn’s Disease Market in France: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.2.4. Crohn’s Disease Market in Spain: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.2.5. Crohn’s Disease Market in Italy: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.2.6. Crohn’s Disease Market in Rest of Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

17.2.3. Crohn’s Disease Market in Asia-Pacific: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.3.1. Crohn’s Disease Market in China: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.3.2. Crohn’s Disease Market in Japan: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.3.3. Crohn’s Disease Market in Australia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.3.4. Crohn’s Disease Market in India: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.3.5. Crohn’s Disease Market in South Korea: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.3.6. Crohn’s Disease Market in Rest of Asia-Pacific: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

17.2.4. Crohn’s Disease Market in Middle East and Africa: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.4.1. Crohn’s Disease Market in Israel: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.4.2. Crohn’s Disease Market in Saudi Arabia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.4.3. Crohn’s Disease Market in United Arab Emirates: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.4.4. Crohn’s Disease Market in Egypt: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

17.2.5. Crohn’s Disease Market in Latin America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.5.1. Crohn’s Disease Market in Brazil: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.5.2. Crohn’s Disease Market in Mexico: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.2.5.3. Crohn’s Disease Market in Argentina: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

17.3. Revenue Shift Analysis: Geographical Regions
17.4. Penetration-Growth (P-G) Matrix: Geographical Regions
17.5. Data Triangulation and Validation

18. CONCLUSION

19. INSIGHTS FROM PRIMARY RESEARCH

20. APPENDIX I: TABULATED DATA

21. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION